ASCO 2011 Roundup
Exelixis Shares Dive on 'Cabo' Safety Data; Prostate Shines
By Staff Reports
Tuesday, June 7, 2011
Investors may be looking to Exelixis Inc. for comfort during the biotech's Monday evening conference call, particularly after a series of analyses from a Phase II trial of cabozantinib (XL184) presented over the weekend at the American Society of Clinical Oncology's (ASCO) 2011 annual meeting sent shares tumbling 20.2 percent.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.